Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 14/20 | 0.50 |
| ▸ | INSR | P06213 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771576 | 0.82 | ITK (0.71) | ITKINSR | |
| SCHEMBL3455619 | 0.75 | KMT2A (0.54) | HPGDKDM4EALDH1A1THRBMEN1 | |
| Methyl Alcohol SCHEMBL11518093 | 0.71 | SMN1; SMN2 (0.72) | HPGDKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25123079 | 0.71 | SMN1; SMN2 (0.76) | HPGDALDH1A1MEN1KMT2ANAMPT | |
| SCHEMBL4522241 | 0.71 | SMN1; SMN2 (0.76) | HPGDALDH1A1MEN1KMT2ANAMPT | |
| SCHEMBL8395225 | 0.71 | SMN1; SMN2 (0.76) | HPGDALDH1A1MEN1KMT2ANAMPT | |
| SCHEMBL1969435 | 0.70 | PTGES (0.48) | HPGDKDM4EALDH1A1THRBMEN1 | |
| SCHEMBL8391563 | 0.69 | SMN1; SMN2 (0.73) | HPGDKDM4EMEN1KMT2ANAMPT | |
| SCHEMBL19465043 | 0.69 | HPGD (0.58) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1725705 | 0.68 | HPGD (0.59) | HPGDKDM4EALDH1A1THRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825219-B2 | NITROGEN COMPOUNDS SUCH AS 4-((5-(CYCLOHEXYL-METHYL-CARBAMOYL) -2(THIOPHENE-2-CARBONYL)-AMINO)BENZIMIDAZOL-1-YL)-BUTYRIC ACID ADMINISTERED FOR THE PROPHYLAXIS OF INFLAMMATORY, IMMUNOLOGICAL AND ALLERGIC DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20030144281-A1 | Substituted benzimidazole compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144281-A1 | Substituted benzimidazole compounds | HRH2, HRH4, HRH1 | ITK 1721/4885INSR 2096/4885HPGD 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.